NCT01687920View on ClinicalTrials.gov

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 17, 2012

Primary Completion Date

November 28, 2012

Study Completion Date

March 21, 2013

Conditions
Heart Failure
Interventions
DRUG

BAY94-8862 (1.25mg)

DRUG

BAY94-8862 (2.5mg)

DRUG

BAY94-8862 (5mg)

DRUG

BAY94-8862 (7.5mg)

DRUG

BAY94-8862 (10mg)

Trial Locations (1)

41061

CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01687920 - Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets | Biotech Hunter | Biotech Hunter